Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy

Table 5

System adverse events compared with baseline.

IVC	IVR	IVTA	value
Cardiovascular disease (case, %)	14 (70.0)	13 (68.4)	14 (73.7)	0.519, 0.333, 0.729
Hypertension (case, %)	15 (75.0)	12 (63.2)	16 (84.2)	1.000, 0.748, 0.439
Cerebral vascular disease (case, %)	6 (30.0)	7 (36.8)	5 (26.3)	0.731, 1.000, 0.712

value of IVC, IVR, and IVTA.